Postmenopausal women with hormone-receptor-positive breast cancer may be prescribed Arimidex as part of endocrine treatment. Arimidex contains anastrozole, an oral aromatase inhibitor that lowers oestrogen production and can slow the growth of oestrogen-dependent tumour cells.
Arimidex is an oral oncology medicine containing anastrozole as its active pharmaceutical ingredient. It belongs to the aromatase inhibitor class and is used mainly in postmenopausal women whose breast cancer depends on oestrogen signalling. The tablets are taken by mouth, usually as part of a planned course of hormone therapy rather than as a short symptom-treatment course.
Aromatase is an enzyme that converts androgen precursors into oestrogens, including estradiol. After menopause, the ovaries produce much less oestrogen, but tissues such as fat, muscle, and breast tissue can still make small amounts through aromatase activity.
Anastrozole blocks this enzyme. The result is a marked reduction in circulating oestrogen and estradiol levels. For an oestrogen-receptor-positive tumour, less hormone stimulation can mean slower cell division and reduced tumour activity.
The FDA prescribing information describes anastrozole as a potent and selective aromatase inhibitor used in postmenopausal breast cancer treatment [1].
| Pharmacological target | Effect of anastrozole |
|---|---|
| Aromatase enzyme | Blocks conversion of androgen precursors into oestrogen |
| Circulating estradiol | Reduces hormone exposure |
| Oestrogen-receptor-positive tumour cells | Removes hormonal stimulation that may support growth |
Tamoxifen works through a different route. It binds to oestrogen receptors and changes how those receptors respond to the hormone. Arimidex reduces oestrogen production itself, while tamoxifen mainly modifies receptor signalling.
This distinction matters when an oncologist chooses endocrine therapy. Treatment selection may change after surgery, during adjuvant therapy, in recurrent disease, or when side effects make one endocrine approach unsuitable.
The active ingredient is anastrozole. Its chemical structure includes a triazole ring and nitrile groups, features that allow the molecule to bind to aromatase and inhibit its activity.
Arimidex is prescribed for specific breast cancer situations. The decision depends on menopausal status, tumour biology, stage, previous treatment, bone health, and the wider oncology plan.
The amount per intake is set individually for each person rather than being one fixed number. Arimidex is taken orally as a tablet, normally once daily, according to the oncology prescription.
A missed dose is usually handled by taking it when remembered unless the next scheduled dose is near. In that situation, the missed tablet is skipped and the regular schedule resumes. Two doses should not be taken together.
Do not crush, chew, or alter a tablet unless the oncology team has specifically advised it. Altering an oral medicine can create swallowing problems and makes dose tracking less reliable.
Arimidex is not suitable for everyone. The medicine requires specialist assessment when pregnancy, breastfeeding, ovarian function, bone disease, liver disease, or previous thromboembolism is relevant.
Anastrozole should not be combined casually with oestrogen-containing medicines because the intended reduction in oestrogen may be opposed. Tamoxifen can also reduce the clinical effect of anastrozole when both are used together, so concurrent treatment requires a clear specialist rationale.
Medicines for bone protection, anticoagulants, antidepressants, pain relievers, and herbal products should be reviewed as part of the oncology medication history. The National Cancer Institute’s 2024 breast cancer treatment information supports reviewing the full treatment list when endocrine therapy is started or changed [4].
Pregnancy prevention remains relevant if ovarian function is possible. Arimidex can harm a developing pregnancy, and it is not used during breastfeeding.
Anastrozole can cause oestrogen-deprivation symptoms and musculoskeletal effects. Side effects vary between individuals, and symptoms may change during the first weeks or months.
| Side-effect pattern | Practical response |
|---|---|
| Hot flushes, sweating, sleep disturbance | Keep the bedroom cool, record triggers, and discuss persistent symptoms |
| Joint pain, stiffness, muscle aches | Gentle strength and mobility exercise may help; report persistent or limiting pain |
| Vaginal dryness or discomfort | Discuss suitable non-hormonal options with the oncology team |
| Reduced bone density | Bone-health assessment, weight-bearing activity, calcium and vitamin D review may be considered |
| Headache, nausea, tiredness | Track severity and timing, especially if symptoms interfere with daily activities |
Clinical safety information also recognises thromboembolic events, including deep vein thrombosis and pulmonary embolism, although the risk profile differs from tamoxifen and depends on the person’s medical history. A DVT may cause one-sided leg swelling, warmth, tenderness, or pain. A pulmonary embolism can cause sudden breathlessness, chest pain, coughing blood, faintness, or a rapid heartbeat. These symptoms require urgent medical assessment rather than waiting for the next oncology appointment [3].
Bone and joint symptoms deserve active management. A patient who stops moving because of stiffness may lose muscle strength and mobility, which can make the original problem feel worse. Gentle activity can preserve function during treatment. Strength and balance exercises may also support bone health. The oncology team can tailor activity to pain, fracture risk, and general fitness. Short walks, supervised resistance exercise, and gradual morning movement can be more realistic than attempting an intense fitness programme immediately.
Arimidex is used in postmenopausal women with hormone-sensitive breast cancer. The treatment plan may involve surgery, radiotherapy, chemotherapy, targeted treatment, or another endocrine medicine, depending on the diagnosis.
Common clinical settings include:
The National Institute for Health and Care Excellence recommends endocrine therapy as part of management for hormone-receptor-positive breast cancer, with treatment choice guided by menopausal status and clinical circumstances [2].
Arimidex does not treat every type of breast cancer. Its value is linked to tumour hormone biology, especially the presence of oestrogen receptors. The pathology report and oncology assessment determine whether an aromatase inhibitor fits the treatment plan.
Arimidex and tamoxifen are both endocrine treatments, but they affect the oestrogen pathway at different points.
| Treatment approach | Main mechanism | Common clinical trade-off |
|---|---|---|
| Anastrozole | Inhibits aromatase and lowers oestrogen production | More joint, muscle, and bone-related concerns |
| Tamoxifen | Modifies oestrogen-receptor signalling | More concern about blood clots and endometrial effects |
| Ovarian suppression plus endocrine therapy | Reduces ovarian hormone production alongside receptor or aromatase effects | More pronounced menopausal symptoms |
In postmenopausal women, aromatase inhibitors are often selected when reducing peripheral oestrogen production offers a suitable balance between recurrence protection and tolerability. Tamoxifen may remain appropriate in other clinical situations, including when bone health or intolerance affects the treatment choice.
Neither option is automatically better for every patient. Tumour characteristics, age, fracture risk, clotting history, previous endocrine therapy, and personal tolerance all influence the decision. A Cochrane review describes aromatase inhibitors as a major component of endocrine treatment for hormone-receptor-positive breast cancer [5].
Several avoidable habits can reduce the benefit of endocrine therapy or make side effects harder to manage:
One useful distinction is between an expected nuisance and a danger signal. Mild stiffness after rest can be documented and discussed. Sudden chest pain, faintness, or breathlessness needs urgent assessment.
In clinical practice, oncologists usually set two expectations early: benefit is measured over months and years, while side effects should be addressed before they threaten adherence.
A doctor will often ask about stiffness, sleep, hot flushes, mood, vaginal symptoms, and physical activity rather than waiting for a patient to volunteer them. These questions are practical because manageable symptoms are less likely to lead to unplanned treatment discontinuation.
Bone health is another routine focus. Depending on the patient’s risk factors, clinicians may assess fracture risk, arrange bone-density testing, recommend weight-bearing exercise, or consider bone-protective treatment.
The treatment decision also reflects pathology. Arimidex is most relevant when the tumour is hormone-receptor-positive and the patient’s hormonal status supports aromatase inhibition. A lower oestrogen level alone does not replace surgery, radiotherapy, chemotherapy, or targeted treatment when those are indicated.
Arimidex should not be used during pregnancy or breastfeeding because suppression of oestrogen can harm a developing pregnancy and the medicine is not intended for nursing infants. The FDA product information (2023) identifies pregnancy as a contraindication and advises against breastfeeding during treatment. Pregnancy potential should be discussed before treatment begins, especially when ovarian function has not been fully suppressed.
Anastrozole has a long elimination half-life, so aromatase inhibition continues beyond a single day and supports once-daily administration. The FDA pharmacology information (2023) describes sustained exposure after repeated dosing, while the clinical purpose is continuous hormone suppression rather than short-term symptom relief. A missed tablet should not be replaced with two tablets because the medicine’s persistence does not justify dose doubling.
The usual approach is to take the missed tablet when remembered unless the next scheduled dose is close. If the next dose is near, the missed dose is skipped and the normal schedule resumes. The FDA prescribing information (2023) supports avoiding unplanned dose doubling after a missed dose and discussing repeated missed doses with the oncology team.
Arimidex contains anastrozole, which inhibits aromatase and reduces oestrogen production. Tamoxifen acts mainly at the oestrogen receptor, changing how the receptor responds to circulating hormone. NICE guidance updated in 2025 describes both endocrine approaches within breast cancer care, with selection based on menopausal status, recurrence risk, adverse effects, and previous therapy .
Arimidex is not usually tapered in the same way as medicines that cause a withdrawal syndrome, but stopping early can reduce the intended duration of endocrine protection. Oestrogen production gradually returns toward the person’s underlying postmenopausal level after treatment ends, although the timing varies. The National Cancer Institute’s 2024 breast cancer treatment information supports discussing planned completion, switching, or interruption with the oncology team rather than stopping because of side effects .
There is no single medically superior time of day for everyone. Taking Arimidex at a consistent time supports adherence, and some patients choose morning dosing so they can observe symptoms during the day. The FDA prescribing information (2023) supports once-daily oral administration, while the practical choice can be matched to sleep, nausea, work, and other medicines.
Arimidex can be taken with food or without food. A light meal may make nausea easier for some patients, although food is not required to activate the medicine. The European Medicines Agency’s 2022 product information for oral medicines emphasises following the approved administration instructions and reporting persistent intolerance during follow-up.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
